Rapid evaluation of the COVID-19 pandemic response in palliative and end of life care: national delivery, workforce and symptom management (CovPall)
- Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
- Total publications:35 publications
Grant number: MR/V012908/1
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$172,361.6Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)Principal Investigator
Prof. Irene HigginsonResearch Location
United KingdomLead Research Institution
King's College LondonResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The COVID-19 pandemic is placing an unprecedented strain on health care services. Although many people survive, an estimated 1 to 4% die from this disease. There are more than 10,000 UK deaths from COVID-19, with numbers escalating. Many of the symptoms, such as breathlessness, fever, agitation and pain, are very distressing. But in this new disease these symptoms are not well understood. Palliative care services are adapting rapidly to this situation, but in different ways, not knowing what is best. This research aims to rapidly evaluate the palliative care response in COVID-19 to improve care now and in the future. There are two main components, called work packages (WPs), to the research. WP1 surveys, UK wide, palliative care medical or nursing leads, about their changes in practice, how they deploy the workforce, volunteers and technology, their innovations and challenges. WP2 collects data about patients' symptoms, how they change over time, and the effects of treatments. We collect this information immediately and quickly (phase I), and then repeat the data collection after 6-8 weeks (phase II) to understand how practice is changing. We involve patients, families, the public, policy makers and services in all stages of the research. We release early findings, to help catalyse an effective response.
Publicationslinked via Europe PMC
Last Updated:14 hours ago
View all publications at Europe PMC